Alexander Spira, MD, PhD, FACP, Discusses Biomarker-Guided Treatment in Lung Cancer at 2021 WCLC

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.

At the 2021 World Conference on Lung Cancer, CancerNetwork® spoke with Alexander Spira, MD, PhD, FACP, of Virginia Cancer Specialists, about the approval of drugs for mutations such as KRAS G12C and how there are more in development to target these aberrations.


Right now, there’s obviously been a big focus on [EGFR] exon 20 insertion [mutations] because we have a drug that’s approved, a drug coming down the pike, and a lot of excitement as well. In the KRAS world, we had a drug approved and likely another one soon in [tumors with mutations in] KRAS G12C. KRAS has been this undruggable target for a long time, but I think the approval of these drugs as well as the excitement of these other drugs has gotten everybody jazzed up. Hopefully, we’ll be able to really advance the field and not only make better drugs for KRAS G12C, but also for other KRAS mutations as well. There’s a few more things coming down the pike, it seems to be an exciting field. What’s exciting for me is that the rest of oncologists in the lung cancer [space] continue to lead the field in terms of targeted personalized therapy.

Related Videos
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Related Content